Free Trial

Boston Scientific (BSX: Baa1/BBB+) 2Q24 Results

HEALTHCARE
  • Strong Results, Strong Guidance
  • Revenue $4.12b +2.6% ahead of expectations
  • Organic growth +14.7% - company had guided for 10.5-12.5%Cardiovascular led the growth with 19% organic
  • Expects FY growth of 13-14% now
  • BSX acquired Axonics and Silk Road recently.
  • Issuance is definitely a possibility post-results.

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.